Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACEPHEN vs ABREVA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Inhibits viral DNA polymerase and DNA synthesis of herpes simplex virus (HSV-1 and HSV-2).
Mild to moderate pain,Fever
Herpes labialis (cold sores) in immunocompetent adults and adolescents ≥12 years
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
Apply a thin layer to the affected area 5 times daily for 4 days.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Due to minimal systemic absorption, an elimination half-life cannot be accurately determined in humans. Following intravenous administration in animals, the terminal half-life is approximately 10 hours, but this is not clinically relevant for topical use.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Docosanol is applied topically with minimal systemic absorption. No significant metabolism occurs. No active metabolites.
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
Docosanol is minimally absorbed after topical application; systemic absorption is negligible. Any absorbed drug is primarily metabolized and excreted via bile and feces. Renal excretion is insignificant. Less than 1% of the applied dose enters systemic circulation, and nearly all elimination occurs via biliary/fecal routes.
Approximately 10-20% bound to serum albumin; extensive tissue binding.
Renally negligible; not extensively studied. For the absorbed fraction, protein binding is presumed to be high (>99%) due to the lipophilic nature of docosanol, binding primarily to albumin and lipoproteins.
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Systemic absorption is minimal; thus Vd is not clinically relevant. Based on animal studies, Vd is estimated to be approximately 1.5 L/kg, reflecting distribution into total body water and lipid compartments.
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
Topical administration: bioavailability is less than 1% due to minimal percutaneous absorption; systemic exposure is negligible. Not administered via other routes.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
No dosage adjustment required.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
No dosage adjustment required.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
Approved for use in patients aged 12 years and older: apply a thin layer 5 times daily for 4 days.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
No specific dosage adjustment required; use same as adult dosing.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
None.
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Not for ophthalmic, intranasal, intravaginal, or intraoral use.,Avoid application to mucous membranes.,Immunocompromised patients: consider alternative therapy for severe infections.,Local irritation or allergic contact dermatitis may occur.
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
Hypersensitivity to docosanol or any component of the formulation.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
No known food interactions. Avoid acidic or spicy foods if they irritate the lesion. Maintain good hydration and nutrition to support immune function.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk. No adequate human studies in pregnant women. Risk to fetus cannot be ruled out, but potential benefits may warrant use. No first trimester-specific risks identified.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
Excretion in human milk unknown. Caution advised. M/P ratio not established.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
No dose adjustment required. Pharmacokinetics not significantly altered in pregnancy.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Apply at first prodromal symptoms (tingling, burning) for maximal efficacy. Avoid application to mucous membranes or inside the nose/mouth. Use a fingertip to apply a thin layer to the lesion; do not share the tube. Lesions should be kept clean and dry; avoid coverings unless instructed. Consider combination therapy with oral antivirals for frequent or severe outbreaks.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
Start applying at the first sign of a cold sore (tingling, itching, or redness).,Wash hands before and after application to prevent spreading the virus.,Apply a small amount (pea-sized) to the affected area, typically 5 times a day until healed.,Do not use on broken skin or mucous membranes (inside mouth, eyes, or genital area).,Avoid kissing or sharing utensils, towels, or lip products while the sore is present.,The tube is for single-patient use only; do not share with others.,May cause mild stinging or redness; if severe irritation occurs, discontinue use.,See a doctor if the sore is severe, lasts longer than 10 days, or you have frequent outbreaks.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACEPHEN vs ABREVA, answered by our medical review team.
ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. ABREVA is a Antiviral that works by Inhibits viral DNA polymerase and DNA synthesis of herpes simplex virus (HSV-1 and HSV-2).. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACEPHEN and ABREVA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. The standard adult dose of ABREVA is: Apply a thin layer to the affected area 5 times daily for 4 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACEPHEN and ABREVA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. ABREVA is classified as Category C. FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk. No adequate human studies in pregnant women. Risk to fetus cannot be ruled out, but potential benefits ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.